Becker's Healthcare September 12, 2024
The FDA has approved Johnson & Johnson’s Tremfya to treat adults with moderate to severe ulcerative colitis.
It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver...